Prothena Reports Fourth Quarter and Full Year 2015 Financial Results; Provides Financial Guidance and R&D Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Prothena (PRTA) Pivotal Trial Readout Coming in 2H18 - Wedbush
February 19, 2016 9:47 AM ESTWedbush analyst, Heather Behanna, expects a potential catalyst for Prothena Corp (NASDAQ: PRTA) in 2H18 when data from the VITAL enrollment is released. A slip in the launch date pressures the price target to $77 but the analyst keeps the Outperform rating.
NEOD001 VITAL enrollment update sets up for pivotal trial readout in 2H18. At this time, Prothena anticipates enrollment to be complete in 2Q17 with data to follow in 12-18 months. As a reminder, VITAL is an event driven study enrolling newly diagnosed AL... More
Prothena Corp. (PRTA) Tops Q2 EPS by 5c
February 18, 2016 4:42 PM ESTProthena Corp. (NASDAQ: PRTA) reported Q2 EPS of ($0.76), $0.05 better than the analyst estimate of ($0.81). Revenue for the quarter came in at $307 thousand versus the consensus estimate of $570 thousand.
For earnings history and earnings-related data on Prothena Corp. (PRTA) click here.
... More